Sanara MedTech (SMTI) Projected to Post Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $26.6250 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Sanara MedTech (NASDAQ:SMTI) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.10. The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Price Performance

NASDAQ:SMTI opened at $28.22 on Wednesday. The business’s 50-day moving average price is $31.88 and its 200 day moving average price is $30.20. The firm has a market cap of $251.16 million, a P/E ratio of -24.33 and a beta of 1.21. Sanara MedTech has a 52-week low of $23.53 and a 52-week high of $39.08. The company has a quick ratio of 2.03, a current ratio of 2.26 and a debt-to-equity ratio of 1.25.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Marshall Wace LLP grew its stake in Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after acquiring an additional 42,237 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Sanara MedTech during the 2nd quarter valued at about $382,000. Lazard Asset Management LLC grew its stake in Sanara MedTech by 63,100.0% during the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after acquiring an additional 3,155 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after acquiring an additional 483 shares in the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SMTI has been the topic of a number of research analyst reports. HC Wainwright lifted their target price on Sanara MedTech from $53.00 to $54.00 and gave the stock a “buy” rating in a report on Monday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Sanara MedTech from a “buy” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $50.00.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.